|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cervical Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Uterine Cervical Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Female | |||||
| Genital Neoplasms, Female | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Urogenital Neoplasms | |||||
| Uterine Cervical Diseases | |||||
| Uterine Diseases | |||||
| Uterine Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| recombinant interleukin-12 | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Interleukin-12 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Adjuvants, Immunologic | |||||
| Angiogenesis Inhibitors | |||||
| Angiogenesis Modulating Agents | |||||
| Antineoplastic Agents | |||||
| Growth Inhibitors | |||||
| Growth Substances | |||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Eastern Cooperative Oncology Group | |||||
| National Cancer Institute (NCI) | |||||